Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Leadless Electrocardiogram (ECG) Evaluation Study (LECG)

This study has been completed.
Information provided by (Responsible Party):
Medtronic Bakken Research Center Identifier:
First received: February 3, 2011
Last updated: February 14, 2014
Last verified: February 2014
Results First Received: December 23, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Supportive Care
Condition: Heart Failure
Interventions: Other: LECG first
Other: Programmer ECG first

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
200 patients were enrolledand were followed for at least 1 month in 25 institutions in France (max 50 patients per center). The first patient was enrolled on 16th of September 2010. The last patient was enrolled on the 13th of September 2011. The last follow-up visit took place on 5th of December 2011.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
The point of enrollment was defined as the time before device implant at which a patient has signed and dated the Informed Consent Form. At that point, the patient needed to be followed for the duration of the study (until the 1-Month Follow-Up visit) unless a Study Exit Form was completed.

Reporting Groups
Overall Subjects Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device

Participant Flow:   Overall Study
    Overall Subjects  
STARTED     195  
COMPLETED     176  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Overall Subjects No text entered.

Baseline Measures
    Overall Subjects  
Number of Participants  
[units: participants]
[units: years]
Mean (Standard Deviation)
  77.6  (9.83)  
[units: years]
Median (Inter-Quartile Range)
  (74 to 84)  
[units: participants]
Female     50  
Male     145  
BMC Index  
[units: kg/m²]
Mean (Standard Deviation)
  25.64  (4.38)  
[units: Kilogramms]
Mean (Standard Deviation)
  72.9  (14.37)  
[units: Kilogramms]
Median (Inter-Quartile Range)
  (63 to 81)  
[units: meters]
Mean (Standard Deviation)
  1.68  (0.09)  
[units: meters]
Median (Inter-Quartile Range)
  (1.62 to 1.75)  
BMC Index  
[units: kg/m²]
Median (Inter-Quartile Range)
  (22.64 to 27.76)  
NYHA Class  
[units: participants]
Class I     6  
Class II     41  
Class III     105  
Class IV     12  
Not available     31  
[units: %]
Mean (Standard Deviation)
  31.67  (8.18)  
[units: %]
Median (Inter-Quartile Range)
  (25 to 35)  
General cardiovascular history  
[units: participants]
Cardiomyopathy     187  
Congenital Heart Disease     2  
Congestive Heart Failure     29  
Coronary artery disease     24  
Hypertension     66  
Myocardial infarction     25  
Pulmonary hypertension (PH)     2  
Valve dysfunction     26  
Other cardiovascular history     17  
Cardiovascular Surgical History  
[units: participants]
NONE     65  
Ablation     16  
Coronary artery bypass graft (CABG)     11  
Coronary artery intervention     43  
Valve surgery     20  
Other cardiovascular surgery     5  
Previous Device  
[units: participants]
CRT-D implant     6  
CRT-P implant     39  
ICD implant     1  
IPG implant     37  
other     5  
Atrial Arrhythmia History  
[units: participants]
NONE     86  
Atrial fibrillation     99  
Atrial flutter     12  
Atrial tachycardia     1  
Premature atrial complexes     1  
Sinus node dysfunction     6  
Supraventricular tachycardia     1  
Other atrial arrhythmias     3  
Ventricular Arrhythmia History  
[units: participants]
NONE     174  
Premature ventricular complexes     7  
Torsades de pointes     1  
Ventricular asystole     1  
Ventricular flutter     1  
Ventricular tachycardia, non-sustained     6  
Ventricular tachycardia, sustained monomorphic     1  
Ventricular tachycardia, sustained, unknown morpho     2  
Other ventricular arrhythmias     3  
AV Junctional Arrhythmia History  
[units: participants]
NONE     44  
1st degree AV block     31  
2nd degree AV block     10  
3rd degree AV block     43  
Intermediate bundle branch block     4  
Left bundle branch block     96  
Right bundle branch block     15  
Other AV junctional arrhythmias and blocks     5  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Patients With LECG Performing Clinically Equivalent to PECG During Standard Pacemaker Follow-up Procedure.   [ Time Frame: 30 to 120 days ]

2.  Secondary:   Evaluation of the Possibility to Determine Ventricle Capture by an Independent Reviewer.   [ Time Frame: 30 to 120 days ]

3.  Secondary:   Evaluation of the Stability of LECG Performance Over Time.   [ Time Frame: 30 to 120 days ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   Quality of LECG in New Devices Versus Device Replacements.   [ Time Frame: 30 to 120 days ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

5.  Secondary:   Effect of Posture Changes and Artifact-inducing Maneuvers on the LECG Quality.   [ Time Frame: 30 to 120 days ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

6.  Secondary:   Evaluation of Factors Such as Device Rotation, Device Fixation, Device Side Facing the Skin, Position of Lead Loops in the Pocket, Use of Antiseptic Solution, Skin Type, Body Mass Index on the Quality of Leadless ECG.   [ Time Frame: 30 to 120 days ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr Françoise Hidden-Lucet
Organization: Hôpital de la Pitié-Salpêtrière
phone: +33 1 42 16 00 00

Responsible Party: Medtronic Bakken Research Center Identifier: NCT01297283     History of Changes
Other Study ID Numbers: Leadless ECG Evaluation Study
Study First Received: February 3, 2011
Results First Received: December 23, 2013
Last Updated: February 14, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: Institutional Ethical Committee
France: Conseil National de l'Ordre des Médecins